Developmental Therapeutics Research Program

UWCCC开发治疗学（DT）计划摘要 联合负责人：Glenn Liu、Shigeki Miyamoto和Jing Zhang 项目总结/摘要 UW Carbone癌症中心（UWCCC）开发治疗（DT）计划的使命是 通过发现新靶点、开发治疗剂和生物标志物， 并将这项研究转化为早期临床试验。DT计划提供了翻译方向 不仅适用于DT成员，而且适用于UWCCC内的其他计划（例如GEM，VR，TM）。临床试验数据和 资源为我们了解反应和抗性机制提供了信息，并使我们能够识别 新的治疗靶点和治疗策略，以改善临床结果。DT计划有59个核心 委员来自十八个学系及五间不同的学校/学院。DT成员的研究影响 证明了研究奖励总额超过2250万美元的年度直接成本的同行评审和非同行 审查的资金（包括345万美元的NCI，620万美元的癌症相关的其他NIH机构，497万美元的同行评审 非NIH来源，790万美元非同行评审资金）和大量出版物（1228 出版物，其中18%来自计划内合作，24%来自计划间合作 工作）。 新的UWCCC战略运营计划的一个关键组成部分是进一步加强和发展 创新疗法和癌症生物标志物。根据这一战略目标， DT计划的目标是：1）发现癌症治疗的新分子靶点; 2）开发新的药物， 生物标志物;和3）将新疗法和生物标志物转化为临床试验。为了实现这一目标， 有一个非常强大的项目，发现，开发和翻译新的干预措施和生物标志物。到 为此，DT计划的成员来自基础科学，应用科学和临床部门。 该计划的专业知识范围从基本发现（分子途径和目标）， （药物/检测/生物标志物），到早期临床翻译应用（1期临床试验）。平移和 临床研究DT计划成员将计划内和计划间的研究发现应用于临床 试验，进行大多数首次在人体或早期临床试验，而个别疾病特异性 研究团队（疾病导向团队）主要专注于2期和3期研究。DT成员领导或 参与所有临床研究小组，促进翻译和反向翻译的机会。

UWCCC Developmental Therapeutics (DT) Program Summary Co-Leaders: Glenn Liu, Shigeki Miyamoto, and Jing Zhang PROJECT SUMMARY/ABSTRACT The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes by discovering new targets, developing therapeutic agents and biomarkers, and translating this research into early phase clinical trials. The DT Program provides the translational direction not only for DT members, but for other programs within the UWCCC (e.g. GEM, VR, TM). Clinical trial data and resources inform our understanding of response and resistance mechanisms and enable the identification of new therapeutic targets and treatment strategies to improve clinical outcomes. The DT Program has 59 core members, representing 18 departments and 5 different schools/colleges. Research impacts of DT members are evidenced by research awards totaling over $22.5M in annual direct cost of peer-reviewed and non-peer reviewed funding (including $3.45M NCI, $6.2M cancer-related other NIH agencies, $4.97M peer-reviewed non-NIH sources, $7.9M non-peer reviewed funding) and a significant number of publications (1228 publications, 18% of which result from intra-programmatic collaboration and 24% from inter-programmatic work). A key component of the new UWCCC Strategic Operating Plan is to further strengthen and develop Innovative Therapies and Cancer Biomarkers. Consistent with this strategic goal, the thematic aims of the DT Program are to: 1) discover new molecular targets for cancer therapy; 2) develop new agents and biomarkers; and 3) translate new therapies and biomarkers into clinical trials. To achieve this goal, it is critical to have a very strong program that discovers, develops, and translates novel interventions and biomarkers. To this end, members of the DT Program come from basic science, applied science, and clinical departments. This program has expertise ranging from basic discovery (molecular pathways and targets), to development (drugs/assays/biomarkers), to early clinical translation application (Phase 1 clinical trials). Translational and clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical trials, performing the majority of first-in-human or early phase clinical trials, while individual disease-specific research teams (Disease Oriented Teams) focus primarily on phase 2 and 3 studies. DT members lead or participate in all clinical research groups facilitating both translational and reverse-translational opportunities.